Graig Suvannavejh
Stock Analyst at Mizuho
(2.44)
# 2,366
Out of 4,711 analysts
137
Total ratings
47.12%
Success rate
-1.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADAP Adaptimmune Therapeutics | Maintains: Outperform | $3 → $1.5 | $0.60 | +147.97% | 2 | Nov 27, 2024 | |
| AUTL Autolus Therapeutics | Upgrades: Buy | $7 → $7.6 | $2.29 | +231.88% | 1 | Nov 18, 2024 | |
| IMCR Immunocore Holdings | Downgrades: Neutral | $72 → $38 | $28.33 | +34.16% | 7 | Nov 11, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $39 → $38 | $33.21 | +14.42% | 6 | Oct 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $42 → $52 | $34.28 | +51.69% | 15 | Oct 10, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Reiterates: Outperform | $74 | $13.00 | +469.23% | 1 | Sep 20, 2024 | |
| ATHA Athira Pharma | Downgrades: Neutral | $5 → $0.5 | $0.58 | -13.19% | 3 | Sep 19, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $44 → $49 | $46.96 | +4.34% | 6 | Jul 22, 2024 | |
| IDYA IDEAYA Biosciences | Initiates: Outperform | $50 | $25.61 | +95.24% | 1 | Jul 8, 2024 | |
| NMRA Neumora Therapeutics | Initiates: Outperform | $20 | $10.85 | +84.33% | 1 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $96 → $100 | $83.45 | +19.83% | 9 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $106 | $90.73 | +16.83% | 16 | Jun 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $82 | $70.44 | +16.41% | 6 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $6.85 | +133.58% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $4.05 | -25.93% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $30 | $7.10 | +322.54% | 4 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $22 | $4.74 | +364.14% | 4 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $8 | $2.00 | +300.00% | 1 | Apr 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 | $4.99 | -29.86% | 1 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $10 | $5.86 | +70.65% | 5 | Nov 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $9 | $1.86 | +383.87% | 4 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $0.34 | +1,073.02% | 8 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $1.70 | +782.35% | 1 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $56.12 | -37.63% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $8.65 | -7.51% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $48.87 | +16.64% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $32.20 | -84.47% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $3.99 | +752.13% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $6.25 | +348.00% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $30.78 | +0.71% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $19 | $0.87 | +2,090.71% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $2.05 | +131.71% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $14.99 | +140.16% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $26.76 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $1.30 | +2,746.15% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $122.97 | +4.09% | 1 | Sep 14, 2020 |
Adaptimmune Therapeutics
Nov 27, 2024
Maintains: Outperform
Price Target: $3 → $1.5
Current: $0.60
Upside: +147.97%
Autolus Therapeutics
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $2.29
Upside: +231.88%
Immunocore Holdings
Nov 11, 2024
Downgrades: Neutral
Price Target: $72 → $38
Current: $28.33
Upside: +34.16%
Apellis Pharmaceuticals
Oct 24, 2024
Maintains: Neutral
Price Target: $39 → $38
Current: $33.21
Upside: +14.42%
Harmony Biosciences Holdings
Oct 10, 2024
Maintains: Outperform
Price Target: $42 → $52
Current: $34.28
Upside: +51.69%
Corbus Pharmaceuticals Holdings
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $13.00
Upside: +469.23%
Athira Pharma
Sep 19, 2024
Downgrades: Neutral
Price Target: $5 → $0.5
Current: $0.58
Upside: -13.19%
Halozyme Therapeutics
Jul 22, 2024
Maintains: Neutral
Price Target: $44 → $49
Current: $46.96
Upside: +4.34%
IDEAYA Biosciences
Jul 8, 2024
Initiates: Outperform
Price Target: $50
Current: $25.61
Upside: +95.24%
Neumora Therapeutics
Jul 8, 2024
Initiates: Outperform
Price Target: $20
Current: $10.85
Upside: +84.33%
Jun 21, 2024
Maintains: Buy
Price Target: $96 → $100
Current: $83.45
Upside: +19.83%
Jun 12, 2024
Reiterates: Buy
Price Target: $106
Current: $90.73
Upside: +16.83%
Jun 7, 2024
Maintains: Buy
Price Target: $36 → $82
Current: $70.44
Upside: +16.41%
May 16, 2024
Maintains: Buy
Price Target: $14 → $16
Current: $6.85
Upside: +133.58%
May 14, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $4.05
Upside: -25.93%
May 7, 2024
Maintains: Buy
Price Target: $39 → $30
Current: $7.10
Upside: +322.54%
Apr 29, 2024
Maintains: Buy
Price Target: $40 → $22
Current: $4.74
Upside: +364.14%
Apr 2, 2024
Maintains: Buy
Price Target: $20 → $8
Current: $2.00
Upside: +300.00%
Mar 27, 2024
Maintains: Neutral
Price Target: $3.5
Current: $4.99
Upside: -29.86%
Nov 27, 2023
Maintains: Buy
Price Target: $17 → $10
Current: $5.86
Upside: +70.65%
Nov 17, 2023
Maintains: Buy
Price Target: $10 → $9
Current: $1.86
Upside: +383.87%
Aug 23, 2023
Reiterates: Neutral
Price Target: $4
Current: $0.34
Upside: +1,073.02%
Mar 31, 2023
Initiates: Buy
Price Target: $15
Current: $1.70
Upside: +782.35%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $56.12
Upside: -37.63%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $8.65
Upside: -7.51%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $48.87
Upside: +16.64%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $32.20
Upside: -84.47%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $3.99
Upside: +752.13%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $6.25
Upside: +348.00%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $30.78
Upside: +0.71%
Mar 2, 2021
Initiates: Sell
Price Target: $19
Current: $0.87
Upside: +2,090.71%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $2.05
Upside: +131.71%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $14.99
Upside: +140.16%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $26.76
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $1.30
Upside: +2,746.15%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $122.97
Upside: +4.09%